Redx Pharma announced today that it has appointed Lisa Anson as Chief Executive Officer (CEO) and to its Board of Directors. Lisa will take up both roles on 1 June 2018. At that time Iain Ross, currently Executive Chairman, will revert to being Non-Executive Chairman.
Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018.
Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018.
Dr. Pearce Joins as ABIVAX Works with FDA and EMA on Next Stage Developments of its Clinical Product Candidates
Commense, Inc., an affiliate of PureTech Health plc developing microbiome-derived immune modulators for paediatric and maternal health, today announced the appointment of Edward J. Tad Stewart as President and Chief Executive Officer.
Nordic Nanovector ASA announces that Luigi Costa will step down as Chief Executive Officer by mutual agreement with the Board of Directors. A search for a new CEO will begin immediately. To ensure a smooth transition, Mr Costa has agreed to be available to the board until the end of July 2018.
Smith & Nephew plc today announced the appointment of Namal Nawana as Chief Executive Officer. He will join the Company and be appointed to the Board as an Executive Director on 7 May 2018.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.
Rentschler Biopharma SE announced today that Dr. Thomas Rösch will join the Company as Vice President Biopharma Engineering & Technology, effective April 1, 2018. He will be responsible for advanced biopharmaceutical engineering projects to enhance site and capacity.
Hansa Medical AB, a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that the board of directors have appointed Søren Tulstrup as new President and CEO of Hansa Medical effective today March 20, 2018.